‘Brensis’ attracted interests among other highlighted domestic biosimilars
‘Brensis,’ a biosimilar of MSD and Samsung Bioepis, and its follow-up biosimilars have attracted interests. Since domestic biosimilars have competitiveness in quality and price in the global market of biomedicines which have recorded high growths, it was criticized the supporting role of the gove...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
